This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why Dentsply (XRAY) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Dentsply (XRAY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Down -7.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Dentsply (XRAY)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Dentsply (XRAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
XRAY vs. COO: Which Stock Is the Better Value Option?
by Zacks Equity Research
XRAY vs. COO: Which Stock Is the Better Value Option?
XRAY vs. COO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
XRAY vs. COO: Which Stock Is the Better Value Option?
DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q1 earnings and revenues decline year over year, driven by the unfavorable foreign currency movement and soft demand across all geographical segments.
Compared to Estimates, Dentsply (XRAY) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Dentsply (XRAY) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
What's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter 2023 results are likely to reflect strong performance in the Technologies & Equipment business.
West Pharmaceutical Services (WST) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 18.56% and 2.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
XRAY or COO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
XRAY vs. COO: Which Stock Is the Better Value Option?
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
DENTSPLY SIRONA (XRAY) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q4 earnings and revenues decline year over year due to unfavorable foreign currency movement and soft demand across all geographical segments.
What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect strong performance in the Technologies & Equipment business.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
DENTSPLY SIRONA's (XRAY) Preliminary FY22 Sales Meet Estimates
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) preliminary results meet market expectation. While certain product categories are driving growth, macro headwinds continue to hurt the top line.
Why Is Dentsply (XRAY) Up 1% Since Last Earnings Report?
by Zacks Equity Research
Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Despite a year-over-year decline in both earnings and revenues, DENTSPLY SIRONA's (XRAY) third-quarter results benefit from the Technologies & Equipment business.
What's in Store for DENTSPLY SIRONA (XRAY) in Q3 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) third-quarter results are likely to reflect strong performance in the Technologies & Equipment business.
Analysts Estimate Cardinal Health (CAH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.
DexCom and Papa John's International have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
DexCom and Papa John's International are part of the Zacks Bull and Bear of the Day article.
3 Stocks From the Growing Digital Orthodontic Space in Focus
by Urmimala Biswas
The orthodontic treatment market has experienced substantial recovery, primarily owing to the easing of restrictions and mass opening up of the economy in 2022.
The Cooper Companies (COO) Lags Q3 Earnings Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of -0.31% and 1.44%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?
DENTSPLY SIRONA (XRAY) Falls After Nasdaq's Delinquency Notice
by Zacks Equity Research
The Nasdaq exchange issues a notice to DENTSPLY SIRONA (XRAY) for filing delinquency from the exchange and for non-compliance with the Nasdaq Listing Rules. Shares fall.
Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and 57.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?